1. Home
  2. BESS vs LGVN Comparison

BESS vs LGVN Comparison

Compare BESS & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bimergen Energy Corporation Common Stock

BESS

Bimergen Energy Corporation Common Stock

N/A

Current Price

$2.75

Market Cap

21.6M

Sector

N/A

ML Signal

N/A

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$6.99

Market Cap

21.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BESS
LGVN
Founded
1998
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.6M
21.4M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
BESS
LGVN
Price
$2.75
$6.99
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
53.9K
374.8K
Earning Date
03-31-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.76
EPS
N/A
N/A
Revenue
$168,880.00
$709,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$10.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.00
$0.48
52 Week High
$6.45
$7.36

Technical Indicators

Market Signals
Indicator
BESS
LGVN
Relative Strength Index (RSI) 41.17 80.16
Support Level $2.55 $0.61
Resistance Level $3.17 $7.30
Average True Range (ATR) 0.22 0.44
MACD -0.01 0.15
Stochastic Oscillator 5.06 90.22

Price Performance

Historical Comparison
BESS
LGVN

About BESS Bimergen Energy Corporation Common Stock

Bimergen Energy Corp is a renewable energy project developer that enables the clean energy transition and provides critical grid stability via solutions across a range of applications through portfolio of utility-scale Battery Energy Storage System (BESS) and solar development projects. Its portfolio includes approximately 23 development-stage utility-scale BESS projects with a projected total storage capacity of around 1.965 gigawatts (GW) and approximately 13 development-stage solar energy projects expected to generate around 1.640 GW upon completion and operation.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: